Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine)

Drug Metabolism and Disposition

Volumn 32, Issue 9, 2004, Pages 1001-1007

  Pizarro, Nieves ^a   Farré, Magí ^a   Pujadas, Mitona ^a   Peiró, Ana Ma ^a   Roset, Pere N ^a   Joglar, Jesús ^b   De La Torre, Rafael ^a,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b DEPARTMENT OF ENVIRONMENTAL CHEMISTRY   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; CARBON; CATECHOL DERIVATIVE; DRUG METABOLITE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CHIRALITY; COGNITION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; ENANTIOMER; ENANTIOSELECTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; MOOD; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RACEMIC MIXTURE; REACTION TIME; STEREOCHEMISTRY;

3,4-METHYLENEDIOXYAMPHETAMINE; ADMINISTRATION, ORAL; AREA UNDER CURVE; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 CYP2D6; DEOXYEPINEPHRINE; HALF-LIFE; HUMANS; MALE; METHAMPHETAMINE; METHODS; PHENOTYPE; POLYMORPHISM, GENETIC; STEREOISOMERISM;

EID: 4143098459     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Brunnenberg M and Kovar K-A (2001) Stereospecific analysis of ecstasy-like N-ethyl-3,4-methylenedioxyamphetamine and its metabolites in humans. J Chromatogr B 751:9-18.
2. Camí J, Farré M, Mas M, Roset PN, Poudevida S, Mas A, San L, and de la Torre R (2000) Human pharmacology of 3,4- methylenedioxymethamphetamine ("Ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20:455-466.
3. Curran HV and Travill RA (1997) Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA, ecstasy): week-end "high" followed by mid-week low. Addiction 92:821-831.
4. de Boer D, Tan LP, Gorter P, van de Wal RM, Kettenes-van den Bosch JJ, de Bruijn EA, and Maes RA (1997) Gas chromatographic/mass spectrometric assay for profiling the enantiomers of 3,4-methylenedioxymethamphetamine and its chiral metabolites using positive chemical ionization ion trap mass spectrometry. J Mass Spectrom 32:1236-1246.
5. Delaforge M, Jaouen M, and Bouille G (1999) Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP2D. Environ Toxicol Pharmacol 7:153-158.
6. de la Torre R, Farré M, Roset PN, Pizarro N, Segura J, and Cami J (2000a) Pharmacology of MDMA in humans, Ann NY Acad Sci 914:225-237.
7. de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Segura J, and Camí J (2000b) Non-linear pharmacokinetics of MDMA ("ecstasy") in humans, Br J Clin Pharmacol 49:104-109.
8. de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, and Cami J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism and disposition. Ther Drug Monit 26:137-144.
9. Ensslin HK, Maurer HH, Gouzoulis E, Hermle L, and Kovar K-A (1996) Metabolism of racemic 3,4-methylenedioxymethamphetamine in humans. Isolation, identification, quantification and synthesis of urinary metabolites. Drug Metab Dispos 24:813-820.
10. Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, and Hutt AJ (1999) Stereospecific analysis and enantiomeric disposition of 3,4- methylenedioxymethamphetamine (ecstasy) in humans. Clin Chem 45:1058-1069.
11. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, and Woods JH (2003) Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature and locomotor activity in singly housed and crowded mice. Psycopharmacology 166:202-211.
12. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, and Winger G (2002) 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotoninergic involvement. Psycopharmacology 161:356-364.
13. Fitzgerald RL, Blanke RV, and Poklis A (1990) Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. Chirality 4:241-248.
14. Green AR, Mechan AO, JM Elliott, O'Shea E, and Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev 55:463-508.
15. Hensley D and Cody JT (1999) Simultaneous determination of amphetamine, methamphetamine, methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA) and methylenedioxyethylamphetamine (MDEA) enantiomers by GC-MS. J Anal Toxicol 23:518-523.
16. Johnson MP, Hoffman AJ, and Nichols DE (1986) Effects of the enantiomers of MDA. MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269-276.
17. Kreth K, Kovar K, Schwab M, and Zanger UM (2000) Identification of the human cytochrome P450 involved in the oxidative metabolism of "Ecstasy" related designer drugs. Biochem Pharmacol 59:1563-1571.
18. Lanz M, Brenneisen R, and Thormann W (1997) Enantioselective determination of 3,4-methylenedioxymethamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis. Electrophoresis 18:1035-1043.
19. Mas M, Farré M, de la Torre R. Roset PN, Ortuño J, Segura J, and Camí J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136-145.
20. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, and Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ("ecstasy"). Toxicol Lett 112-113:133-142.
21. Meyer A, Mayerhofer A, Kovar K-A, and Schmidt WJ (2002a) Enantioselective metabolism of the designer drugs 3,4-methylenedioxymethamphetamine ("ecstasy") and 3,4-methylenedioxyethylamphetamine ("eve") isomers in rat brain and blood. Neurosci Lett 330:193-197.
22. Meyer A, Mayerhofer A, Kovar K-A. and Schmidt WJ (2002b) Rewarding effects of the optical isomers of 3,4-methylenedioxymethamphetamine ("ecstasy") and 3,4-methylenedioxyethylamphetamine ("eve") measured by conditioned place preference in rats. Neurosci Lett 330:280-284.
23. Monks TJ, Jones DC, Bai F, and Lau SS (2004) The role of metabolism in 3,4(±)-methyledioxyamphetamine and 3,4(±)- methyledioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 26:132-136.
24. Moore KA, Mozayani A, Fierro MF, and Poklis A (1996) Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning. Forensic Sci Int 83:111-119.
25. Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB and the classic hallucinogens, Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305-313.
26. Pizarro N, de la Torre R, Farré M, Segura J, Llebaria A and Joglar I (2002a) Synthesis and capillary electrophoretic analysis of enantiomerically enriched reference standards of MDMA and its main metabolites, Bioorg Med Chem 10:1085-1092.
27. Pizarro N, Llebaria A, Cano S, Farré M, Segura J, and de la Torre R (2003) Method development for stereochemical analysis of MDMA and its main metabolites by GC-MS. Rapid Commun Mass Spectrom 17:330-336.
28. Pizarro N, Ortuño J, Farré M, Hernández-López C, Pujadas M, Llebaria A, Joglar J, Roset PN, Mas M, Segura J, et al. (2002b) Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 26:157-165.
29. Schmid B, Bircher J, Preisig R, and Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624.
30. Segura M, Ortuño J, Farré M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J and de la Torre R (2001) 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14:1203-1208.
31. Segura M, Ortuno J, McLure JA, Pujadas M, Pizarro N, Farre M, Llebaria A, Joglar J, Segura J, and de la Torre R (2002) High-performance liquid chromatography with electrochemical detection applied to the analysis of 3,4-dihydroxymethamphetamine in human plasma and urine. J Chromatogr B 769:313-321.
32. Spitzer M, Franke B, Walter H, Buechler J, Wunderlich AP, Schwab M, Kovar K-A, Hermle L, and Grön G (2001) Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans. Neuropharmacology 41:263-271.
33. White SR, Obradovic T, Imel KM, and Wheaton MJ (1996) The effects of methylenedioxymeth-amphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 49:455-479.